Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gonadotropin-releasing hormone receptor (type 1) (GnRHR)
- Target
- GnRHR
- Molecular classification
- G protein-coupled receptor, Receptor
01
Overview
The gonadotropin-releasing hormone receptor is a rhodopsin-like, class A GPCR on anterior pituitary gonadotrope cells that binds hypothalamic GnRH to activate predominantly Gq/11, leading to phospholipase C activation, IP3/DAG signaling, Ca2+ mobilization, and secretion of LH and FSH; it is also expressed in several extra-pituitary tissues and certain tumors. Human type 1 GnRHR uniquely lacks a cytoplasmic C-terminal tail (helix 8) compared with most class A GPCRs; recent structural work has resolved antagonist-bound human GnRH1R and defined features of its orthosteric pocket relevant for drug design (e.g., elagolix binding). Mutations in conserved transmembrane networks of the receptor can impair expression or function and are linked to congenital hypogonadotropic hypogonadism.
- Other names
- Luteinizing hormone-releasing hormone receptor (LHRHR)GnRH receptorGnRH1 receptor (GnRH1R)
02
Mechanism of action
Antagonists: competitively block GnRHR to rapidly suppress LH/FSH release and downstream gonadal steroids; Agonists: initially stimulate GnRHR (LH/FSH surge) but sustained exposure downregulates/desensitizes the receptor leading to hypogonadism and reduced gonadotropin release
03
Biological functions
Signal transduction via Gq/11–PLC–IP3/DAG–Ca2+ pathwaysRegulation of luteinizing hormone and follicle-stimulating hormone secretionControl of reproductive function and steroidogenesis
04
Disease associations
Cancer (expression in breast, prostate, ovary; investigated antiproliferative signaling)Reproductive endocrine disorders (e.g., congenital hypogonadotropic hypogonadism from GnRHR mutations)
05
Safety considerations
Hypoestrogenism or hypogonadism-related effects (e.g., hot flashes, bone mineral density loss) due to suppression of gonadal steroids with chronic GnRHR modulationDisease flare with GnRH agonists due to initial LH/FSH surge before downregulation (mitigated by antagonists)
06
Interacting drugs
GnRH receptor antagonists: elagolix; relugolix; degarelix; cetrorelix
1 more in the full profile.
07
Biomarkers
Pituitary LH and FSH levels as pharmacodynamic readouts of GnRHR modulationCirculating sex steroids (estradiol, testosterone) as downstream biomarkers of efficacy
Beyond the preview
Go deeper on Gonadotropin-releasing hormone receptor (type 1) (GnRHR).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gonadotropin-releasing hormone receptor (type 1) (GnRHR).